A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy
- Resource Type
- Article
- Source
- In
Cancer Treatment and Research Communications 2021 28 - Subject
- Language
- ISSN
- 2468-2942